SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-22-032260
Filing Date
2022-06-10
Accepted
2022-06-10 16:35:12
Documents
14
Period of Report
2022-06-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea161325-8k_tffpharmace.htm   iXBRL 8-K 33913
2 OPEN MARKET SALE AGREEMENT DATED AS OF JUNE 10, 2022 BETWEEN THE COMPANY AND JEF ea161325ex1-1_tffpharmace.htm EX-1.1 216784
3 OPINION OF GREENBERG TRAURIG, LLP ea161325ex5-1_tffpharmace.htm EX-5.1 8294
  Complete submission text file 0001213900-22-032260.txt   494550

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE tffp-20220610.xsd EX-101.SCH 3036
5 XBRL LABEL FILE tffp-20220610_lab.xml EX-101.LAB 34476
6 XBRL PRESENTATION FILE tffp-20220610_pre.xml EX-101.PRE 22597
8 EXTRACTED XBRL INSTANCE DOCUMENT ea161325-8k_tffpharmace_htm.xml XML 3714
Mailing Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746
Business Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746 737-802-1973
TFF Pharmaceuticals, Inc. (Filer) CIK: 0001733413 (see all company filings)

IRS No.: 824344737 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39102 | Film No.: 221009447
SIC: 2834 Pharmaceutical Preparations